CGAS and malignant colon neoplasm: These results suggest that cGAS/STING activation in colon cancer patients likely results in elevated PD-L1 expression and that upregulation of PD-L1 by 5-FU and oxaliplatin may be one of the mechanisms of chemoresistance in colon cancer treatment.